{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Colorectal+Neoplasia", "query": { "condition": "Advanced Colorectal Neoplasia" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 941, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Colorectal+Neoplasia&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-11-12T08:52:10.618Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03277209", "title": "To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreas Cancer" ], "interventions": [ { "name": "Plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-07-25", "completion_date": "2019-12-30", "has_results": false, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-11-12T08:52:10.618Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03277209" }, { "nct_id": "NCT03761914", "title": "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Ovarian Cancer", "Colorectal Cancer", "Triple-negative Breast Cancer", "Small-cell Lung Cancer" ], "interventions": [ { "name": "galinpepimut-S", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Montanide", "type": "OTHER" }, { "name": "GM-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Sellas Life Sciences Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2019-09-30", "completion_date": "2022-10-27", "has_results": true, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-11-12T08:52:10.618Z", "location_count": 12, "location_summary": "Santa Rosa, California • Whittier, California • Miami, Florida + 9 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03761914" }, { "nct_id": "NCT03549000", "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)", "Triple Negative Breast Cancer (TNBC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Colorectal Cancer Microsatellite Stable (MSS)", "Ovarian Cancer", "Renal Cell Carcinoma (RCC)", "Metastatic Castration Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "NZV930", "type": "OTHER" }, { "name": "PDR001", "type": "OTHER" }, { "name": "NIR178", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2018-07-18", "completion_date": "2022-10-17", "has_results": false, "last_update_posted_date": "2024-12-13", "last_synced_at": "2026-11-12T08:52:10.618Z", "location_count": 2, "location_summary": "Tampa, Florida • Houston, Texas", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03549000" }, { "nct_id": "NCT07292298", "title": "Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Adenocarcinoma", "Rectal Cancer" ], "interventions": [ { "name": "High Rare Dose Rectal Brachytherapy Boost", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 44, "start_date": "2026-11", "completion_date": "2031-11", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-11-12T08:52:10.618Z", "location_count": 3, "location_summary": "Aurora, Colorado • Rochester, New York • Portland, Oregon", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Rochester", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07292298" }, { "nct_id": "NCT07822399", "title": "A Study of MGC030 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Cancer", "GastroEsophageal Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gastric Cancer (GC)", "Pancreatic Cancer" ], "interventions": [ { "name": "MGC030", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2026-10-07", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-12T08:52:10.618Z", "location_count": 1, "location_summary": "Lake Success, New York", "locations": [ { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07822399" }, { "nct_id": "NCT03250832", "title": "Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "TSR-033", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-08-08", "completion_date": "2023-02-13", "has_results": true, "last_update_posted_date": "2024-04-11", "last_synced_at": "2026-11-12T08:52:10.618Z", "location_count": 11, "location_summary": "Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03250832" }, { "nct_id": "NCT00499733", "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cryoablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 19, "start_date": "2007-06", "completion_date": "2013-01-09", "has_results": false, "last_update_posted_date": "2019-01-18", "last_synced_at": "2026-11-12T08:52:10.618Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499733" }, { "nct_id": "NCT03058289", "title": "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "Lymphoma", "Pancreatic Cancer", "Liver Cancer", "Colon Cancer", "Lung Cancer", "Bile Duct Cancer", "Chordoma of Sacrum", "Sarcoma" ], "interventions": [ { "name": "INT230-6", "type": "DRUG" }, { "name": "anti-PD-1 antibody", "type": "BIOLOGICAL" }, { "name": "anti-CTLA-4 antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Intensity Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-02-09", "completion_date": "2023-02-22", "has_results": true, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-11-12T08:52:10.618Z", "location_count": 7, "location_summary": "Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03058289" }, { "nct_id": "NCT03849469", "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Cervical Carcinoma", "Pancreatic Carcinoma", "Triple Negative Breast Cancer", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced or Metastatic Solid Tumors", "Prostate Carcinoma", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Intrahepatic Cholangiocarcinoma", "Squamous Cell Anal Cancer", "Squamous Cell Penile Carcinoma", "Squamous Cell Vulvar Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma" ], "interventions": [ { "name": "XmAb®22841", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (Keytruda®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-05-29", "completion_date": "2023-02-16", "has_results": false, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-11-12T08:52:10.618Z", "location_count": 28, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03849469" }, { "nct_id": "NCT05783622", "title": "Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Renal Cell Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Colorectal Carcinoma", "Small Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Triple-negative Breast Cancer" ], "interventions": [ { "name": "JANX008", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janux Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 130, "start_date": "2023-04-19", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-11-12T08:52:10.618Z", "location_count": 18, "location_summary": "Duarte, California • Sacramento, California • San Diego, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05783622" } ] }